OR WAIT 15 SECS
The organization released principles related to workforce development, diversity, and inclusion that it believes are key to the biotechnology industry.
On June 19, 2017, the Biotechnology Innovation Organization (BIO) released a set of principles on workforce development, diversity, and inclusion (WDDI) for the biotechnology industry. BIO also established a board-level WDDI Committee charged with working to foster workforce development, diversity, and inclusion at BIO and throughout the biotech industry. The committee will be chaired by Helen Torley, president and CEO of Halozyme, who is succeeding Julie Gerberding, executive vice-president and chief patient officer at Merck, who led the committee as it developed BIO’s WDDI principles over the last year.
The principles on WDDI adopted today by BIO’s Board of Directors state that BIO considers diversity to be essential to the success of the biotechnology industry. In a press release, the organization named the following principles as key to this plan.
The organization will also discuss workforce development, diversity, and inclusion during the 2017 BIO International Convention in San Diego, CA from June 19–22, 2017.